218 related articles for article (PubMed ID: 31587594)
1. Primary small intestinal neuroendocrine tumors are highly prevalent and often multiple before metastatic disease develops.
Eriksson J; Norlén O; Ögren M; Garmo H; Ihre-Lundgren C; Hellman P
Scand J Surg; 2021 Mar; 110(1):44-50. PubMed ID: 31587594
[TBL] [Abstract][Full Text] [Related]
2. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of gastroenteropancreatic neuroendocrine tumours.
Fraenkel M; Kim MK; Faggiano A; Valk GD
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):691-703. PubMed ID: 23582913
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H
World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
6. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.
Alwan H; La Rosa S; Andreas Kopp P; Germann S; Maspoli-Conconi M; Sempoux C; Bulliard JL
Cancer Med; 2020 Dec; 9(24):9454-9461. PubMed ID: 33078908
[TBL] [Abstract][Full Text] [Related]
7. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
Garcia-Carbonero R
Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
[No Abstract] [Full Text] [Related]
8. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
9. Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors.
Singh S; Chan DL; Moody L; Liu N; Fischer HD; Austin PC; Segelov E
JAMA Oncol; 2018 Apr; 4(4):583-585. PubMed ID: 29543939
[TBL] [Abstract][Full Text] [Related]
10. Secondary malignancy in patients with sporadic neuroendocrine neoplasia.
Krausch M; Raffel A; Anlauf M; Schott M; Lehwald N; Krieg A; Kröpil F; Cupisti K; Knoefel WT
Endocrine; 2013 Oct; 44(2):510-6. PubMed ID: 23494366
[TBL] [Abstract][Full Text] [Related]
11. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?
Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE
Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986
[TBL] [Abstract][Full Text] [Related]
12. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
[TBL] [Abstract][Full Text] [Related]
13. The Risk of Second Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Nationwide Population-Based Study.
Stemann Lau T; Dam G; Jepsen P; Grønbæk H; Krogh K; Gregersen T
Neuroendocrinology; 2018; 107(3):280-283. PubMed ID: 30092588
[TBL] [Abstract][Full Text] [Related]
14. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?
DePalo DK; Lee RM; Lopez-Aguiar AG; Gamboa AC; Rocha F; Poultsides G; Dillhoff M; Fields RC; Idrees K; Nathan H; Abbott D; Maithel SK; Russell MC;
J Surg Oncol; 2019 Nov; 120(6):919-925. PubMed ID: 31385621
[TBL] [Abstract][Full Text] [Related]
15. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases.
Estrozi B; Bacchi CE
Clinics (Sao Paulo); 2011; 66(10):1671-5. PubMed ID: 22012036
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Das S; Dasari A
Curr Oncol Rep; 2021 Mar; 23(4):43. PubMed ID: 33719003
[TBL] [Abstract][Full Text] [Related]
18. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
[TBL] [Abstract][Full Text] [Related]
19. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
20. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
